Spruce Biosciences annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Spruce Biosciences Stock-Based Compensation Growth & History (SPRB)
Spruce Biosciences's stock-based compensation was $2.6M for fiscal 2025.
View full Spruce Biosciences company overviewSpruce Biosciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.6M | −$2.8M | −51.87% |
| 2024 | 2024-12-31 | $5.3M | $726,000 | +15.71% |
| 2023 | 2023-12-31 | $4.6M | $991,000 | +27.29% |
| 2022 | 2022-12-31 | $3.6M | −$327,000 | −8.26% |
| 2021 | 2021-12-31 | $4.0M | $3.2M | +424.24% |
| 2020 | 2020-12-31 | $755,000 | $559,000 | +285.20% |
| 2019 | 2019-12-31 | $196,000 | — | — |
Spruce Biosciences quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $871,000 | $948,000 | — |
| Q1 2026 | 2026-03-31 | $689,000 | $145,000 | +26.65% |
| Q4 2025 | 2025-12-31 | $1.7M | $731,000 | +76.07% |
| Q3 2025 | 2025-09-30 | $415,000 | −$725,000 | −63.60% |
| Q2 2025 | 2025-06-30 | −$77,000 | −$1.8M | — |
| Q1 2025 | 2025-03-31 | $544,000 | −$1.0M | −65.17% |
| Q4 2024 | 2024-12-31 | $961,000 | −$260,000 | −21.29% |
| Q3 2024 | 2024-09-30 | $1.1M | $18,000 | +1.60% |
| Q2 2024 | 2024-06-30 | $1.7M | $466,000 | +38.23% |
| Q1 2024 | 2024-03-31 | $1.6M | $502,000 | +47.36% |
| Q4 2023 | 2023-12-31 | $1.2M | $419,000 | +52.24% |
| Q3 2023 | 2023-09-30 | $1.1M | $339,000 | +43.30% |
| Q2 2023 | 2023-06-30 | $1.2M | $314,000 | +34.70% |
| Q1 2023 | 2023-03-31 | $1.1M | −$81,000 | −7.10% |
| Q4 2022 | 2022-12-31 | $802,000 | $5,000 | +0.63% |
| Q3 2022 | 2022-09-30 | $783,000 | −$248,000 | −24.05% |
| Q2 2022 | 2022-06-30 | $905,000 | −$105,000 | −10.40% |
| Q1 2022 | 2022-03-31 | $1.1M | $21,000 | +1.88% |
| Q4 2021 | 2021-12-31 | $797,000 | $388,000 | +94.87% |
| Q3 2021 | 2021-09-30 | $1.0M | $813,000 | +372.94% |
| Q2 2021 | 2021-06-30 | $1.0M | $914,000 | +952.08% |
| Q1 2021 | 2021-03-31 | $1.1M | $1.1M | +3400.00% |
| Q4 2020 | 2020-12-31 | $409,000 | — | — |
| Q3 2020 | 2020-09-30 | $218,000 | $156,000 | +251.61% |
| Q2 2020 | 2020-06-30 | $96,000 | — | — |
| Q1 2020 | 2020-03-31 | $32,000 | — | — |
| Q3 2019 | 2019-09-30 | $62,000 | — | — |
Spruce Biosciences stock-based compensation trends
Over the last five fiscal years, Spruce Biosciences's stock-based compensation increased from $755,000 to $2.6M, a change of $1.8M. The latest reported quarter, Q2 2026, shows $871,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Spruce Biosciences source filings ↗